2.99
+0.18(+6.41%)
Currency In USD
| Previous Close | 2.81 |
| Open | 2.77 |
| Day High | 3.02 |
| Day Low | 2.77 |
| 52-Week High | 7.8 |
| 52-Week Low | 2.38 |
| Volume | 901,767 |
| Average Volume | 466,992 |
| Market Cap | 192.08M |
| PE | -1.93 |
| EPS | -1.55 |
| Moving Average 50 Days | 3.74 |
| Moving Average 200 Days | 4.8 |
| Change | 0.18 |
If you invested $1000 in Inozyme Pharma, Inc. (INZY) since IPO date, it would be worth $170.47 as of December 22, 2024 at a share price of $2.99. Whereas If you bought $1000 worth of Inozyme Pharma, Inc. (INZY) shares 3 years ago, it would be worth $445.6 as of December 22, 2024 at a share price of $2.99.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 27, 2024 1:30 PM GMT
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel fun
Inozyme Pharma to Present at Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 11, 2024 1:30 PM GMT
BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare diseases that affect bone health and blood vessel fun
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
GlobeNewswire Inc.
Nov 05, 2024 1:30 PM GMT
- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in pediatric patients with ENPP1 Deficiency, expected in early